Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lissa Hooi

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
ACS Applied Materials & Interfaces|November 14, 2019
Nanodiamond-Mediated Delivery of a G9a Inhibitor for Hepatocellular Carcinoma TherapyMengjie Gu, Tan Boon Toh, Lissa Hooi, et al.
Journal of Hepatology|September 22, 2019
Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinomaTan Boon Toh, Jhin Jieh Lim, Lissa Hooi, et al.
Oncogenesis|January 19, 2026
The role of histone demethylase PHF2 as a tumour suppressor in hepatocellular carcinoma by regulating SRXN1Dexter Kai Hao Thng, Lissa Hooi, Wai Khang Yong, et al.
Nanoscale|September 20, 2021
Enhanced penetrative siRNA delivery by a nanodiamond drug delivery platform against hepatocellular carcinoma 3D modelsJingru Xu, Mengjie Gu, Lissa Hooi, et al.
Theranostics|October 24, 2022
Addressing antimicrobial resistance with the IDentif.AI platform: Rapidly optimizing clinically actionable combination therapy regimens against nontuberculous mycobacteriaDevika Mukherjee, Peter Wang, Lissa Hooi, et al.
Angewandte Chemie (International Ed. in English)|April 5, 2019
Dual-Targeting Dual-Action Platinum(IV) Platform for Enhanced Anticancer Activity and Reduced NephrotoxicityMaria V Babak, Yang Zhi, Bertrand Czarny, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 15, 2022
Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitorsJhin Jieh Lim, Lissa Hooi, Yock Young Dan, et al.
Biomaterials|January 23, 2018
Generation of matched patient-derived xenograft in vitro-in vivo models using 3D macroporous hydrogels for the study of liver cancerEliza Li Shan Fong, Tan Boon Toh, Quy Xiao Xuan Lin, et al.
Data in Brief|June 15, 2018
Datasets describing the growth and molecular features of hepatocellular carcinoma patient-derived xenograft cells grown in a three-dimensional macroporous hydrogelEliza Li Shan Fong, Tan Boon Toh, Quy Xiao Xuan Lin, et al.
Advanced Therapeutics|August 25, 2020
Project IDentif.AI: Harnessing Artificial Intelligence to Rapidly Optimize Combination Therapy Development for Infectious Disease InterventionAynur Abdulla, Boqian Wang, Feng Qian, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
ACS Applied Materials & Interfaces|November 14, 2019
Nanodiamond-Mediated Delivery of a G9a Inhibitor for Hepatocellular Carcinoma TherapyMengjie Gu, Tan Boon Toh, Lissa Hooi, et al.
Journal of Hepatology|September 22, 2019
Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinomaTan Boon Toh, Jhin Jieh Lim, Lissa Hooi, et al.
Oncogenesis|January 19, 2026
The role of histone demethylase PHF2 as a tumour suppressor in hepatocellular carcinoma by regulating SRXN1Dexter Kai Hao Thng, Lissa Hooi, Wai Khang Yong, et al.
Nanoscale|September 20, 2021
Enhanced penetrative siRNA delivery by a nanodiamond drug delivery platform against hepatocellular carcinoma 3D modelsJingru Xu, Mengjie Gu, Lissa Hooi, et al.
Theranostics|October 24, 2022
Addressing antimicrobial resistance with the IDentif.AI platform: Rapidly optimizing clinically actionable combination therapy regimens against nontuberculous mycobacteriaDevika Mukherjee, Peter Wang, Lissa Hooi, et al.
Angewandte Chemie (International Ed. in English)|April 5, 2019
Dual-Targeting Dual-Action Platinum(IV) Platform for Enhanced Anticancer Activity and Reduced NephrotoxicityMaria V Babak, Yang Zhi, Bertrand Czarny, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 15, 2022
Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitorsJhin Jieh Lim, Lissa Hooi, Yock Young Dan, et al.
Biomaterials|January 23, 2018
Generation of matched patient-derived xenograft in vitro-in vivo models using 3D macroporous hydrogels for the study of liver cancerEliza Li Shan Fong, Tan Boon Toh, Quy Xiao Xuan Lin, et al.
Data in Brief|June 15, 2018
Datasets describing the growth and molecular features of hepatocellular carcinoma patient-derived xenograft cells grown in a three-dimensional macroporous hydrogelEliza Li Shan Fong, Tan Boon Toh, Quy Xiao Xuan Lin, et al.
Advanced Therapeutics|August 25, 2020
Project IDentif.AI: Harnessing Artificial Intelligence to Rapidly Optimize Combination Therapy Development for Infectious Disease InterventionAynur Abdulla, Boqian Wang, Feng Qian, et al.
Pageof 3